Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients

HIV Medicine

Volumn 8, Issue 2, 2007, Pages 131-134

  Mallolas, J ^a   Sarasa, M ^a   Nomdedeu, M ^a   Soriano, A ^a   Lopez Pua Y ^a   Blanco, J L ^a   Martinez E ^a   Gatell, J M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Atazanavir; Pharmacokinetic interaction; Rifampicin

Indexed keywords

ATAZANAVIR; CYTOCHROME P450 3A4; RIFAMPICIN; RITONAVIR; VIRUS RNA;

ADULT; AREA UNDER THE CURVE; ARTICLE; CASE REPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG INHIBITION; DRUG METABOLISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MYCOBACTERIUM TUBERCULOSIS; OPPORTUNISTIC INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; STEADY STATE; TREATMENT OUTCOME; TUBERCULOSIS; VIRUS INHIBITION; VIRUS REPLICATION; WILD TYPE;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIBIOTICS, ANTITUBERCULAR; AREA UNDER CURVE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; MALE; OLIGOPEPTIDES; PROSPECTIVE STUDIES; PYRIDINES; RIFAMPIN; RITONAVIR; TUBERCULOSIS;

EID: 33847773022     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2007.00442.x     Document Type: Article

References (20)

1. Mocroft A, Katlama C, Johnson AM et al. AIDS across Europe, 1994-98: The EuroSIDA Study. Lancet 2000; 356: 291-296.
2. Dean GL, Edwards SG, Ives NJ et al. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS 2002; 16: 75-83.
3. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992; 90: 1871-1878.
4. Finch CK, Chrisman CR, Baciewicz AM et al. Rifampin and rifabutin drug interactions: An update. Arch Intern Med 2002; 162: 985-992.
5. Paine MF, Wagner DA, Hoffmaster KA et al. Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin. Clin Pharmacol Ther 2002; 72: 524-535.
6. Greiner B, Eichelbaum M, Fritz P et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999; 104: 147-153.
7. Chiba M, Hensleigh M, Nishime JA, Balani SK, Lin JH. Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug Metab Dispos 1996; 24: 307-314.
8. Kim RB, Fromm MF, Wandel C et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998; 101: 289-294.
9. Veldkamp AI, Hoetelmans RM, Beijnen JH et al. Ritonavir enables combined therapy with rifampin and saquinavir. Clin Infect Dis 1999; 29: 15-86.
10. Centers for Disease Control and Prevention. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. Morb Mortal Wkly Rep 2000; 49: 185-189.
11. Grange S, Schutz M, Schmitt C, Riek M, Gaudeul-Ehrhart E. Unexpected hepatotoxicity observed in a healthly volunteer study on the effects of multiple dose rifampicin on the steady-state pharmacokinetics of ritonavir-boosted saquinavir and vice versa. 6th International Workshop on Clinical Pharmacology of HIV Therapy. Quebec, Canada, April 2005 [Abstract 35].
12. La Porte CJL, Colbers EPH, Bertz R et al. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother 2004; 48: 1553-1560.
13. Goldsmith DR, Perry CM. Atazanavir. Drugs 2003; 63: 1679-1693.
14. Burger D, Agarwala S, Child M, Been-Tiktak A, Wang Y, Bertz R. Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy subjects. Antimicrob Agents Chemother 2006; 50: 3336-3342.
15. Sarasa-Nacenta M, López-Púa Y, Mallolas J, Blanco JL, Gatell JM, Carné X. Simultaneous determination of the HIV-protease inhibitors indinavir, amprenavir, ritonavir, saquinavir and nelfinavir in human plasma by reversed-phase high performance liquid chromatography. J Chromatography 2001; 757: 325-332.
16. Kappelhoft BS, Huitema AD, Crommentuyn KM et al. Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1 infected patients. Br J Clin Pharmacol 2004; 59: 174-182.
17. Gutmann H, Fricker G, Drewe J, Toeroek M, Miller DS. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol Pharmacol 1999; 56: 383-389.
18. Aarnoutse RE, Wasmuth JC, Fätkenheuer G et al. Administration of indinavir and low-dose ritonavir (800/100mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir. Antivir Ther 2003; 8: 309-314.
19. Gotzkowsky SK, Weidler J, Tonkin J et al. Cytochrome P450 (CYP) 3A4 and 2D6 activities are decreased in HIV-infected subjects. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, Sept 1999 [Abstract 656].
20. López-Cortés LF, Ruiz-Valderas R, Viciana P et al. Pharmacokinetic interactions between efavirenz and rifampin in HIV-infected patients with tuberculosis. Clin Pharmacokinet 2002; 41: 681-690.